-+ 0.00%
-+ 0.00%
-+ 0.00%

Emmaus Life Sciences’ net loss more than doubles to $4.74 million for three months ended Sept. 30, 2026

PUBT·11/19/2026 01:05:37
Listen to the news
Emmaus Life Sciences’ net loss more than doubles to $4.74 million for three months ended Sept. 30, 2026
  • Emmaus Life Sciences’ net loss more than doubled year over year to $4.74 million for the three months ended September 30, 2026.
  • Net revenues fell 44% to $1.89 million due to lower direct Endari sales following the NeoImmuneTech licensing agreement.
  • Operating expenses declined 22% to $1.89 million, primarily due to the sales force transfer to NeoImmuneTech.
  • Cash and cash equivalents fell 54% to $971,000 at September 30, 2026, compared with December 31, 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261118995848) on November 19, 2026, and is solely responsible for the information contained therein.